Drugs / MK-3866
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03295266 | Dec 2017 → Mar 2018 | liver disorder | Merck Sharp & Dohme LLC | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT03259087 | Sep 2017 → Jan 2018 | impaired renal function disease | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MK-3866 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03259087 ↗ |
| Route | Intravenous | “Participants receive a single IV infusion of 200 mg MK-3866 over 30 minutes on Day 1.” NCT03259087 ↗ |